{"id":"W2973037195","doi":"10.1016/s1474-4422(19)30283-2","title":"Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study","year":2019,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Institute on Aging; Johnson and Johnson Pharmaceutical Research and Development; Fuel Cell Technologies Program; Fifth Framework Programme; Canadian Institutes of Health Research; Parkinsonfonden; Danone Research Centre for Specialised Nutrition; European Regional Development Fund; European Research Council; GE Healthcare; Fondation Segré; H. Lundbeck A/S; Marcus och Amalia Wallenbergs minnesfond; National Institute of Biomedical Imaging and Bioengineering; Amsterdam Neuroscience; Skånes universitetssjukhus; Pfizer Pharmaceuticals; Innovative Medicines Initiative; AXA Research Fund; Fondation Plan Alzheimer; Servier; American Liver Foundation; Knut och Alice Wallenbergs Stiftelse; Australian Government; Lunds Universitet; Vetenskapsrådet; NIHR Imperial Biomedical Research Centre; Foundation for the National Institutes of Health; Eisai; UCLH Biomedical Research Centre; Fondation pour la Recherche sur la Biodiversite; Hôpitaux Universitaires de Genève; Fondation Vaincre Alzheimer; Bundesministerium für Bildung und Forschung; Alzheimer Nederland; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Institut National de la Santé et de la Recherche Médicale; Boehringer Ingelheim; Seventh Framework Programme; Novartis Pharmaceuticals Corporation; Merck; Association pour la Recherche sur le Cancer; DoD Alzheimer's Disease Neuroimaging Initiative; Alzheimer's Disease Neuroimaging Initiative; Meso Scale Diagnostics; Biogen; Agence Nationale de la Recherche; F. Hoffmann-La Roche; Alzheimer's Association; European Federation of Pharmaceutical Industries and Associations; Takeda Pharmaceutical Company; Hjärnfonden; AstraZeneca; European Commission; AbbVie; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Novartis; Bristol-Myers Squibb; Eli Lilly and Company; Roche; ZonMw; National Institutes of Health; Alzheimer's Drug Discovery Foundation; Nederlandse Brandwonden Stichting; National Science Foundation; Fundação para a Ciência e a Tecnologia; EU Joint Programme – Neurodegenerative Disease Research; Oryzon Genomics; Sweden-America Foundation","keywords":"Dementia; Biomarker; Oncology; Medicine; Cohort; Alzheimer's Disease Neuroimaging Initiative; Internal medicine; Disease; Gerontology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006103706,0.0001846508,0.0004682115,0.0001061182,0.0001088929,0.00002527838,0.0001600259,0.00005027807,0.0001526535],"category_scores_gemma":[0.00002826051,0.0001090416,0.00008574509,0.0002435274,0.00008703238,0.00003865568,0.00005998824,0.0002498229,0.00006821555],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000139912,"about_ca_system_score_gemma":0.0001111135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000043753,"about_ca_topic_score_gemma":0.00004708407,"domain_scores_codex":[0.998253,0.0002251134,0.0001870533,0.000429023,0.0003251911,0.0005806412],"domain_scores_gemma":[0.9988173,0.0005048894,0.00007606964,0.0003008149,0.0002149454,0.00008603151],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0200901,0.001549092,0.9758101,0.0001395564,0.0002996452,0.00003806662,0.0004248518,0.0001397746,0.0002191622,0.00002033241,0.0004576299,0.0008116689],"study_design_scores_gemma":[0.02532546,0.03028013,0.8942174,0.00007730902,0.0005126309,0.00004795461,0.0007513696,0.04677094,0.0009832254,0.00008040624,0.0007403378,0.0002128277],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9818131,0.00004032184,0.002545784,0.007994708,0.00007218525,0.006502436,0.00002370404,0.00007168939,0.0009360837],"genre_scores_gemma":[0.9942933,0.000009191228,0.0001497883,0.003799003,0.0001116026,0.001322796,0.00003257205,0.00003520376,0.0002465596],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08159271,"threshold_uncertainty_score":0.4446589,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05165167316379238,"score_gpt":0.332468020614417,"score_spread":0.2808163474506246,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}